Germany· DE-A57-99961841ea006a22
Proparakain-Pos
A proxymetacaine product containing proxymetacaine hydrochloride, registered in Germany by Ursapharm Arzneimittel Gmbh. The same ATC class is registered in 10 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Proxymetacaine is registered in 10 of 19 countries.
Countries holding a registration under ATC S01HA04 (proxymetacaine), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 6 of them publish a price we can compare per daily dose
Proxymetacaine · ATC S01HA04
10 / 19 countries
- Belgiumprice
- Canada
- Germany
- Icelandprice
- Ireland
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Proxymetacaine Hydrochloride
- Manufacturer
- Ursapharm Arzneimittel Gmbh
- Country
- Germany (DE)
- ATC code
- S01HA04
- ATC class
- Proxymetacaine
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
20 interactions on record for proxymetacaine.
Graded by severity as the source publishes them — 20 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Proxymetacaine · interactions on record
20 records
- 20 moderate
Most severe, free to view
- MetoclopramideA03FA01moderate
- SulfamethizoleB05CA04moderate
- LidocaineC01BB01moderate
- Silver sulfadiazineD06BA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Proxymetacaine in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesAlcaineAlcon Laboratories, Inc.
- PolandAlcaineInPharm Sp. z o.o.
- NorwayAlcaineAlcon Nordic A/S
- United KingdomMinims proxymetacaine 0.5% eye drops 0.5ml unit doseBausch & Lomb UK Ltd
- BelgiumAlcaine 0.5 %Alcon
- IcelandAlcaineAlcon Nordic A/S
- IrelandMinims Proxymetacaine hydrochloride 0.5% w/v, Eye Drops, SolutionBausch + Lomb Ireland Limited
- CanadaALCAINEALCON CANADA INC
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Belgium · Alcaine
- Bulgaria · Алкаин
- Cyprus · Alcaine
- United Kingdom (Northern Ireland) · Proxymetacaine Hydrochloride Minims Bausch & Lomb Uk
- Greece · Alcaine
- Ireland · Minims
- Iceland · Alcaine
- Lithuania · Alcaine
- Norway · Alcaine
- Poland · Alcaine
- Slovenia · Alcaine
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2a956960-42bb-4323-a90e-653dc8b74a58 GET /v1/drugs/2a956960-42bb-4323-a90e-653dc8b74a58?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Ocular Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Proxymetacaine Hydrochloride",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about proxymetacaine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.